NICE decisions and age
Year | Appraisal | Decision | Age restriction |
2010 | Rheumatoid arthritis—certolizumab | Yes | No |
Soft tissue sarcoma—trabectedin | Yes | No | |
Hearing impairment cochlear implants |
|
| |
2009 | Abdominal aortic aneurysm—endovascular stent grafts | Yes—unruptured | No |
Influenza—zanamivir, amantadine and oseltamivir (review) | Yes—at risk | Relaxed at risk criteria >65 years | |
Renal cell carcinoma—sunitinib | Yes | No | |
Venous thromboembolism—rivaroxaban | Yes | No | |
Head and neck cancer (squamous cell cancer)—cetuximab | No | NA | |
Multiple myeloma—lenalidomide | Yes | No | |
Hepatitis B—tenofovir disoproxil fumarate | Yes | No | |
Leukaemia (chronic lymphocytic, first line)—rituximab | Yes | No | |
Colorectal cancer (first line)—cetuximab | Yes if operable | No | |
Eczema (chronic)—alitretinoin | Yes if severe | No | |
Renal cell carcinoma—bevacizumab, sorafenib and temsirolimus | No | NA | |
Gastrointestinal stromal tumours—sunitinib | Yes | No | |
Lung cancer (non-small cell, first line treatment)—pemetrexed | Yes | No | |
Psoriasis-ustekinumab | Yes if severe | No | |
Acute coronary syndrome—prasugrel | No except emergencies and DM | NA | |
Cervical cancer (recurrent)—tapotecan | No except patient naive | NA | |
Lung cancer (small cell)—tapotecan | Yes if CAV (cyclophosphamide, doxorubicin and vincristine) contraindicated | No | |
2008 | Mesothelioma—pemtrexed disodium | Yes (if WHO performance status 0 or 1) | No |
Psoriasis—infliximab | Yes if severe | No | |
Lymphoma (follicular non-Hodgkin's)—rituximab | Yes | No | |
Structural imaging in first episode psychosis | No | NA | |
Asthma (in adults) corticosteroids | Yes | >12 years | |
Sleep apnoea—continuous positive airway pressure | Yes if moderate or worse | No | |
Rheumatoid arthritis (refractory)—abatacept | No | NA | |
Ulcerative colitis (subacute manifestations)—infliximab | No | NA | |
Anaemia (cancer treatment induced)—erythropoietin (alpha and beta) and darbepoetin | No except non-transfusable and some cases of ovarian cancer | NA | |
Ankylosing spondylitis—adalimumab, etanercept and infliximab | Yes if severe | No | |
Head and neck cancer—cetuximab | No | NA | |
Lung cancer (non-small cell)—bevacizumab (terminated appraisal) | |||
Psoriasis-adalimumab | Yes if severe | No | |
Coronary artery disease—drug-eluting stents | No except small/long lesions | No | |
Diabetes—insulin pump therapy | Yes under 12s | Child–adult distinction | |
Hepatitis B—entecavir | Yes | No | |
Hepatitis B—telbivudine | No | NA | |
Macular degeneration (age-related)—ranibizumab and pegaptanib | Yes ranibizumab No pegaptanib | No | |
Pregnancy (rhesus negative women)—routine anti-D | Yes | No | |
Venous thromboembolism—dabigatran | Yes | No | |
Osteoporosis—primary prevention | Yes with restrictions | Yes | |
Osteoporosis—secondary prevention including strontium ranelate | Yes with restrictions | Yes | |
Pain (chronic neuropathic or ischaemic)—spinal cord stimulation | Yes—severe | No | |
Lung cancer (non-small cell)—erlotinib | Yes | No | |
Organ preservation (renal)—machine perfusion and static storage | Yes | No | |
Hyperuricaemia—febuxostat | No—unless allopurinol not possible | NA | |
Ulcerative colitis (acute exacerbations)—infliximab | Yes—if ciclosporin inappropriate | No |